Big Pharma plans for compensating Indian trial deaths highlights need for guidelines
This article was originally published in SRA
Executive Summary
Multinationals including Bayer and Pfizer appear to have got the ball rolling towards working out compensation payable for clinical trial-related deaths in India, though the absence of "finalised" guidelines on such compensation may be slowing down the process.